Pomerantz Law Firm Brings Class Action Against BioAge Labs Over Alleged Securities Fraud

Class Action Lawsuit Against BioAge Labs: A Call to Shareholders

A recent announcement from the Pomerantz Law Firm has sparked attention regarding BioAge Labs, Inc. The firm has initiated a class action lawsuit against the company, claiming that BioAge has been involved in securities fraud and has engaged in unlawful business practices.

Background of the Case

The lawsuit emerges after BioAge conducted its Initial Public Offering (IPO) on September 26, 2024, where they sold 12.65 million shares priced at $18.00 each. However, the situation took a dramatic turn when, on December 6, 2024, BioAge disclosed that it would stop its ongoing STRIDES Phase 2 study for azelaprag, a drug candidate, due to adverse liver reactions noted in some participants. Following this shocking announcement, the price of BioAge's stock plummeted by $15.44, marking a staggering decline of 76.85%. The stock closed at just $4.65 on December 9, 2024.

Who Should Get Involved?

Investors who have purchased or obtained BioAge securities during the Class Period are urged to reach out to the Pomerantz Law Firm to explore their options. If you fall into this category, you have until March 10, 2025, to request the Court to appoint you as a Lead Plaintiff for this class action. By doing so, you can join other affected shareholders in seeking restitution for potential losses incurred due to the alleged fraudulent practices of BioAge and its directors and officers.

Taking Action

For those interested in learning more about joining this class action, Pomerantz has set up a dedicated contact channel. Interested shareholders can reach out to Danielle Peyton via email at [email protected] or by calling 646-581-9980. It's recommended that individuals include their contact information and details about their share purchases when reaching out.

About Pomerantz LLP

Pomerantz LLC, known for its expertise in corporate, securities, and antitrust litigation, has been a champion for shareholders for over 85 years. Founded by the respected attorney Abraham L. Pomerantz, the firm has a proven track record of securing multimillion-dollar settlements for clients affected by securities fraud and corporate misconduct. Their dedication has established them as one of the leading firms in class action lawsuits.

Conclusion

The case against BioAge Labs is a critical development for investors affected by the recent declines in the company’s shares. As the class action progresses, shareholders must stay informed about their rights and avenues for potential recourse. For more details or to obtain a copy of the Complaint, visit Pomerantz Law Firm’s website. Investors should act promptly to protect their investments and interests in the ongoing class action lawsuit.